- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Clinical Updates in Psoriatic Arthritis
The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.
Risankizumab Receives FDA Approval for Active Psoriatic Arthritis
January 24, 2022
On Jan. 21, AbbVie announced the FDA granted approval to their IL-23 inhibitor risankizumab-rzaa (SKYRIZI) for treatment of active psoriatic arthritis in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.
SF-36 Mental Component Score Predicts Polyarthritis in Patients With PsA
January 07, 2022
Among patients with psoriatic arthritis, a 36-item Short Form Health Survey was the best predictor of progression from oligoarticular to polyarticular arthritis.
Apremilast Improves Quality of Life in Patients With PsA
January 05, 2022
Patient-reported outcomes, in addition to physician assessment, suggest apremilast improves quality of life and symptoms of psoriatic arthritis within 6 months.
Safety Profile Similar in Upadacitinib and Adalimumab for Patients With PsA
January 04, 2022
“As the therapeutic landscape for PsA evolves, evaluating the long-term safety of treatments is essential to understand benefit–risk profiles and inform patient care,” investigators explained.
FDA Approves Secukinumab for Pediatric Patients with PsA and ERA
December 23, 2021
Secukinumab is the only biologic treatment in the US that’s approved by the FDA for children and adolescents with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
Overdrive Podcast: Pain Improvement and Patient-Reported Outcomes in Patients with Psoriatic Arthritis
December 22, 2021
Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.
FDA Approves Upadacitinib (RINVOQ) for Treatment of Active Psoriatic Arthritis
December 15, 2021
The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.
Philip Mease, MD: Guselkumab Achieves Long-term Improvements in Psoriatic Arthritis Symptoms
December 01, 2021
Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).
Louis Bessette, MD, MSc: Pain Improvement and Patient-Reported Outcomes in Patients with Psoriatic Arthritis
November 30, 2021
Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.
Ana-Maria Orbai, MD, FACR, MHS: Guselkumab Improves PROMIS-29 Scores in Patients With Psoriatic Arthritis
November 25, 2021
Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.